$447.97
Price
$113.7B
Market Cap
26.6
P/E Ratio
20.9
Forward P/E
$16.84
EPS (TTM)
—
Dividend Yield
$7.2B
Cash
$2.0B
Total Debt
254M
Shares Out
$362.50
$507.92
52-Week Range
Institutional Ownership of VERTEX PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Tweedy Browne Co.|Thomas Shrager
|
40.4K | $18M | $350.62 | +33.29% |
Trading Activity for VERTEX PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2026-Q1 | |||||
| BUY | +3.4% | 40.4K | $18M | $467.87 | |
| 2025-Q3 | |||||
| BUY | +4.9% | 39.1K | $15M | $395.92 | |
| SELL | -3.7% | 16.3K | $6M | $395.92 | |
| 2025-Q2 | |||||
| SELL | -2.8% | 37.3K | $17M | $450.27 | |
| BUY | +7.4% | 16.9K | $8M | $450.27 | |
| 2025-Q1 | |||||
| SELL | -5.7% | 38.3K | $19M | $474.50 | |
| SELL | -1.8% | 15.7K | $8M | $474.50 | |
| 2024-Q4 | |||||
| SELL | EXIT | — | — | $468.13 | |
| SELL | -24.2% | 40.6K | $16M | $468.13 | |
| BUY | +1.6% | 16.0K | $6M | $468.13 | |
| 2024-Q3 | |||||
| BUY | NEW | 124.0K | $58M | $480.30 | |
| SELL | -1.4% | 53.6K | $25M | $480.30 | |
| BUY | +13.0% | 15.8K | $7M | $480.30 | |
| 2024-Q2 | |||||
| SELL | -18.5% | 54.3K | $25M | $429.93 | |
| BUY | +0.3% | 13.9K | $7M | $429.93 | |
| 2024-Q1 | |||||
| SELL | -0.1% | 66.7K | $28M | $420.74 | |
| SELL | -1.2% | 13.9K | $6M | $420.74 | |
| 2023-Q4 | |||||
| SELL | -11.0% | 66.8K | $27M | $363.04 | |
| BUY | NEW | 14.1K | $6M | $363.04 | |
| SELL | EXIT | — | — | $363.04 | |
| 2023-Q3 | |||||
| BUY | NEW | 75.0K | $26M | $349.53 | |
| BUY | +15.3% | 755 | $262544 | $349.53 | |
| 2023-Q2 | |||||
| BUY | NEW | 655 | $230501 | $339.37 | |
| 2022-Q1 | |||||
| SELL | EXIT | — | — | $235.54 | |
| 2021-Q4 | |||||
| BUY | NEW | 2.9K | $638000 | $187.09 | |
Insider Trading for VERTEX PHARMACEUTICALS INC
6 Months Insider Sentiment
Buy $0
Sell $40.5M
0
Buys
17
Sells
-40.5M
Net
21
Grants
Largest
$7.1M
Leiden
$5.5M
Leiden
$4.7M
Leiden
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | GRANT | 2.1K | — | — |
| Jan 22, 2026 | Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | GRANT | 3.9K | — | — |
| Jan 22, 2026 | Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | GRANT | 3.9K | — | — |
| Jan 22, 2026 | Charles F Wagner JR | EVP, CO & FO | GRANT | 9.4K | — | — |
| Jan 22, 2026 | David Altshuler | EVP, Chief Scientific Officer | GRANT | 3.3K | — | — |
| Jan 22, 2026 | David Altshuler | EVP, Chief Scientific Officer | GRANT | 7.9K | — | — |
| Jan 22, 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | GRANT | 4.7K | — | — |
| Jan 22, 2026 | Jeffrey M Leiden | Executive Chairman | GRANT | 9.0K | — | — |
| Jan 22, 2026 | Carmen Bozic | EVP and CMO | GRANT | 3.5K | — | — |
| Jan 22, 2026 | Jonathan Biller | EVP and Chief Legal Officer | GRANT | 2.8K | — | — |
| Jan 22, 2026 | Jonathan Biller | EVP and Chief Legal Officer | GRANT | 6.3K | — | — |
| Jan 22, 2026 | Kristen Ambrose | SVP & Chief Accounting Officer | GRANT | 1.3K | — | — |
| Jan 22, 2026 | Kristen Ambrose | SVP & Chief Accounting Officer | GRANT | 3.0K | — | — |
| Jan 22, 2026 | Amit Sachdev | EVP Chief Patient & Ext Af Off | GRANT | 3.9K | — | — |
| Jan 22, 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | GRANT | 3.9K | — | — |
| Jan 22, 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | GRANT | 7.9K | — | — |
| Jan 22, 2026 | Reshma Kewalramani | CEO & President | GRANT | 11.9K | — | — |
| Jan 22, 2026 | Reshma Kewalramani | CEO & President | GRANT | 27.0K | — | — |
| Jan 22, 2026 | Carmen Bozic | EVP and CMO | GRANT | 7.9K | — | — |
| Jan 22, 2026 | Amit Sachdev | EVP Chief Patient & Ext Af Off | GRANT | 7.9K | — | — |
| Jan 22, 2026 | Charles F Wagner JR | EVP, CO & FO | GRANT | 4.2K | — | — |
| Jan 07, 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | SELL | 4.5K | $474.99 | $2.1M |
| Jan 06, 2026 | Charles F Wagner JR | EVP, CO & FO | SELL | 9.5K | $461.00 | $4.4M |
| Jan 06, 2026 | Charles F Wagner JR | EVP, CO & FO | EXERCISE | 9.5K | $189.38 | $1.8M |
| Dec 04, 2025 | Jeffrey M Leiden | Executive Chairman | EXERCISE | 1 | $91.05 | $91 |
| Dec 03, 2025 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | SELL | 4.5K | $449.99 | $2.0M |
| Dec 03, 2025 | Charles F Wagner JR | EVP, CO & FO | SELL | 7.0K | $451.00 | $3.2M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | EXERCISE | 63.8K | $86.52 | $5.5M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 1.2K | $447.05 | $515K |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 1.3K | $441.26 | $582K |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 2.1K | $455.22 | $942K |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 2.3K | $448.78 | $1.0M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 2.5K | $443.21 | $1.1M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 4.4K | $444.36 | $1.9M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 4.5K | $440.40 | $2.0M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 5.8K | $451.20 | $2.6M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 5.9K | $449.84 | $2.6M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 7.9K | $445.56 | $3.5M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 10.4K | $453.34 | $4.7M |
| Dec 03, 2025 | Jeffrey M Leiden | Executive Chairman | SELL | 15.7K | $452.20 | $7.1M |
| Dec 03, 2025 | Jonathan Biller | EVP and Chief Legal Officer | SELL | 347 | $449.00 | $156K |